DEANNA PALACIOS: Open Payments
NPI 1922432616 · BETHLEHEM, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 48 payments from 10 companies in 2025. Trend: 2023 $1,206 · 2024 $1,106 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $207 |
| Axsome Therapeutics, Inc. | 6 | $166 |
| ABBVIE INC. | 10 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Alkermes, Inc. | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| Lundbeck LLC | 1 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: INGREZZA, VRAYLAR, TRINTELLIX, Auvelity, REXULTI, CAPLYTA, ARISTADA, AUSTEDO XR.
Industry payments across PA — which companies pay providers there.
